Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Cüneyt Ünsal,1 Yakup Albayrak,1 Neslihan Albayrak,2 Murat Kuloğlu,3 Kenji Hashimoto41Department of Psychiatry, Namik Kemal University School of Medicine, Tekirdag, Turkey; 2Department of Cardiology, Kirklareli State Hospital, Kirklareli, Turkey; 3Department of Psychiatry, Akdeniz U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	&Uuml;nsal C, Albayrak Y, Albayrak N, Kuloğlu M, Hashimoto K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9c6e136560ef477ca80f306468e212b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9c6e136560ef477ca80f306468e212b0
record_format	dspace
spelling	oai:doaj.org-article:9c6e136560ef477ca80f306468e212b02021-12-02T07:49:46ZReduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine1176-63281178-2021https://doaj.org/article/9c6e136560ef477ca80f306468e212b02013-10-01T00:00:00Zhttp://www.dovepress.com/reduced-serum-paraoxonase-1-pon1-activity-in-patients-with-schizophren-a14659https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Cüneyt Ünsal,1 Yakup Albayrak,1 Neslihan Albayrak,2 Murat Kuloğlu,3 Kenji Hashimoto41Department of Psychiatry, Namik Kemal University School of Medicine, Tekirdag, Turkey; 2Department of Cardiology, Kirklareli State Hospital, Kirklareli, Turkey; 3Department of Psychiatry, Akdeniz University School of Medicine, Antalya, Turkey; 4Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, JapanBackground: Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis.Methods: In the present study, we measured serum PON1 activity and serum levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in patients with schizophrenia, who had been treated with either olanzapine or quetiapine, and in healthy controls. Thirty five patients who had been treated with olanzapine, 29 patients who had been treated with quetiapine, and 32 age, sex, and smoking status-matched healthy control (HC) participants were enrolled. Serum PON1 activity and serum levels of TC, triglyceride, HDL-C, and LDL-C were measured.Results: Serum PON1 activity in the olanzapine group was significantly lower than that of HC and quetiapine groups. Furthermore, serum levels of TC and LDL-C in the olanzapine group were significantly higher than those of quetiapine and HC groups. Interestingly, there was a positive correlation between PON1 activity and HDL-C levels in the olanzapine group.Conclusion: These findings suggest that serum PON1 activity in patients treated with olanzapine was lower than that of HC and quetiapine groups, and that PON1 may play a role in the metabolic side effects associated with olanzapine treatment. A further study to examine the relationship between serum PON1 activity and cardiovascular and metabolic side effects during treatment with SGAs will be of great interest.Keywords: second generation antipsychotics, SGA, atherosclerosis, metabolic, dyslipidemia, LDL-C&Uuml;nsal CAlbayrak YAlbayrak NKuloğlu MHashimoto KDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1545-1552 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 &Uuml;nsal C Albayrak Y Albayrak N Kuloğlu M Hashimoto K Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
description	Cüneyt Ünsal,1 Yakup Albayrak,1 Neslihan Albayrak,2 Murat Kuloğlu,3 Kenji Hashimoto41Department of Psychiatry, Namik Kemal University School of Medicine, Tekirdag, Turkey; 2Department of Cardiology, Kirklareli State Hospital, Kirklareli, Turkey; 3Department of Psychiatry, Akdeniz University School of Medicine, Antalya, Turkey; 4Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, JapanBackground: Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis.Methods: In the present study, we measured serum PON1 activity and serum levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in patients with schizophrenia, who had been treated with either olanzapine or quetiapine, and in healthy controls. Thirty five patients who had been treated with olanzapine, 29 patients who had been treated with quetiapine, and 32 age, sex, and smoking status-matched healthy control (HC) participants were enrolled. Serum PON1 activity and serum levels of TC, triglyceride, HDL-C, and LDL-C were measured.Results: Serum PON1 activity in the olanzapine group was significantly lower than that of HC and quetiapine groups. Furthermore, serum levels of TC and LDL-C in the olanzapine group were significantly higher than those of quetiapine and HC groups. Interestingly, there was a positive correlation between PON1 activity and HDL-C levels in the olanzapine group.Conclusion: These findings suggest that serum PON1 activity in patients treated with olanzapine was lower than that of HC and quetiapine groups, and that PON1 may play a role in the metabolic side effects associated with olanzapine treatment. A further study to examine the relationship between serum PON1 activity and cardiovascular and metabolic side effects during treatment with SGAs will be of great interest.Keywords: second generation antipsychotics, SGA, atherosclerosis, metabolic, dyslipidemia, LDL-C
format	article
author	&Uuml;nsal C Albayrak Y Albayrak N Kuloğlu M Hashimoto K
author_facet	&Uuml;nsal C Albayrak Y Albayrak N Kuloğlu M Hashimoto K
author_sort	&Uuml;nsal C
title	Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
title_short	Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
title_full	Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
title_fullStr	Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
title_full_unstemmed	Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
title_sort	reduced serum paraoxonase 1 (pon1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/9c6e136560ef477ca80f306468e212b0
work_keys_str_mv	AT ampuumlnsalc reducedserumparaoxonase1pon1activityinpatientswithschizophreniatreatedwitholanzapinebutnotquetiapine AT albayraky reducedserumparaoxonase1pon1activityinpatientswithschizophreniatreatedwitholanzapinebutnotquetiapine AT albayrakn reducedserumparaoxonase1pon1activityinpatientswithschizophreniatreatedwitholanzapinebutnotquetiapine AT kuloglum reducedserumparaoxonase1pon1activityinpatientswithschizophreniatreatedwitholanzapinebutnotquetiapine AT hashimotok reducedserumparaoxonase1pon1activityinpatientswithschizophreniatreatedwitholanzapinebutnotquetiapine
_version_	1718399176680669184

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Ejemplares similares